Feedback
Settings

Settings

Goto Application

30,104 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 3,011
1.WO/2026/099721METHOD FOR BACTERIOPHAGE PRODUCTION
WO - 15.05.2026
Int.Class C12N 7/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
02Recovery or purification
 Appl.No PCT/IB2025/061198 Applicant NATIONAL RESEARCH COUNCIL OF CANADA Inventor PETERS, Danielle
Provided is a method for infecting a bacterium, in which a host bacterium is exposed to a phage depolymerase and a bacteriophage. The depolymerase catalyzes degradation of at least one cell-surface or extracellular polysaccharide of the host bacterium, thereby increasing the susceptibility of the host bacterium to infection by the bacteriophage. The method may be used to increase production of the bacteriophage and/or to increase the host range of the bacteriophage. Further provided is use of a phage depolymerase selected from B5, As11, TaPaz, APK2, APK37, and IME200, or a composition comprising the same, for increasing the susceptibility of an A. baumannii to infection by a bacteriophage. The A. baumannii may be an AB030, MRSN 843, MRSN 1183, MRSN 7446, MRSN 15088, MRSN 24008, MRSN 31159, MRSN 31468, or MRSN 32866 strain.
2.WO/2026/097245CRYOPROTECTANT AND USE THEREOF
WO - 15.05.2026
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No PCT/CN2024/130128 Applicant SUZHOU ROCROCK NO.1 BIOTECHNOLOGY CO., LTD. Inventor YIN, Xiushan
, and 1-10 wt % of a zwitterionic donor, wherein the mass percentage is the mass percentage in the cryoprotectant, and the concentration of the pH buffer in the cryoprotectant is greater than 0 and less than or equal to 100 mM.
3.WO/2026/102329METHODS AND COMPOSITIONS FOR PREDICTING RESPONSE TO ONCOLYTIC VIROTHERAPY
WO - 15.05.2026
Int.Class A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
 Appl.No PCT/US2025/054658 Applicant CG ONCOLOGY, INC. Inventor SHEN, Shihpei Pearl
The present invention provides methods for selecting an individual having a solid or lymphatic tumor for treatment with an oncolytic virus, comprising determining a level of one of a coxsackie adenovirus receptor (CXADR) gene and/or a level and/or a mutation of each of one or more Rb/E2F pathway genes (e.g, E2F1, E2F2, E2F3, E2F4, E2F5, RB1, RB2, RB3, CCND1, CCND2, CCND3, CCNE1, CCNE2, CDK2, CDK4, CDK6, CDKN2A (pl6/INK4A), CDKN2B, CDKN2C, CDKN2D) in a biological sample of the individual. The present invention also provides methods of treating a solid or lymphatic tumor in an individual, comprising selecting the individual for treatment with an oncolytic virus and administering an effective amount of the oncolytic virus. The treatment method may further comprise administering an effective amount of an immunomodulator. Also provided are compositions and kits for carrying out the methods.
4.WO/2026/099862IMMUNOGENIC PEPTIDE ANTIBODY CONSTANT REGION MOLECULES
WO - 15.05.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/IL2025/050992 Applicant TROJAN BIO LTD. Inventor BURKOVITZ, Anat
Bispecific antibodies comprising mutations that decrease homodimerization and at least one immunogenic peptide inserted into a CHI or CL domain are provided. Proteins comprising an Fc variant of a parent Fc polypeptide wherein at least one immunogenic peptide is inserted into the parent Fc polypeptide and the insertion replaces amino acids of the parent Fc polypeptide are provided. Protein dimers and antibodies comprising the proteins of the invention are also provided as are nucleic acid molecules encoding same, pharmaceutical compositions comprising same and methods of treating cancer by administrating same. Methods of producing antibodies are also provided.
5.WO/2026/099408NOVEL DIAGNOSTIC AND THERAPEUTIC APPROACHES FOR OROPOUCHE VIRUS INFECTION
WO - 15.05.2026
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
 Appl.No PCT/EP2025/082237 Applicant INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE Inventor AMARA, Ali
The present invention reveals MESD as a critical host dependency factor for Oropouche virus (OROV) infection. Initial identification was achieved through a CRISPR-Cas9 loss-of-function screen, which highlighted MESD amongst other potential factors. The ensuing research demonstrated that MESD knockout in HEK293T cells resulted in a significant reduction in OROV infection rates. Complementing MESDKO cells with FLAG-MESD re-established susceptibility, thus confirming MESD's essential role in the infection process. Interestingly, MESD specifically facilitates OROV infection without enhancing the infectivity of other viruses such as LACV, TOSCV, and WNV. The specificity of MESD for OROV was further validated by its interaction with OROV envelope glycoproteins, as shown through immunoprecipitation assays. These findings suggest that targeting MESD could be a novel and effective approach for diagnosing and treating OROV infections, potentially paving the way for innovative therapeutic strategies against this virus.
6.WO/2026/096970EPSTEIN-BARR VIRUS ANTIGENS AND RELATED USES
WO - 07.05.2026
Int.Class A61K 39/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
 Appl.No PCT/US2025/053653 Applicant VACCINE COMPANY, INC. Inventor WEIDENBACHER, Payton, Anders-Benner
Provided herein are engineered Epstein-Barr virus (EBV) polypeptides, polynucleotides encoding the same, related vectors and vaccine compositions, and related methods of making and using said compositions. The compositions disclosed herein may be useful for vaccination against EBV.
7.WO/2026/096416AFFINITY RESINS FOR THE PURIFICATION OF HEPATITIS B SURFACE ANTIGEN
WO - 07.05.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/US2025/052775 Applicant REPLIGEN CORPORATION Inventor KEARNS, Kelley
Provided are affinity ligands that bind to Hepatitis B surface antigen (HBsAg), affinity resins comprising the HBsAg-binding ligands, and related compositions and methods for the isolation and/or purification of HBsAg.
8.20260125656BACULOVIRUS EXPRESSION SYSTEM
US - 07.05.2026
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No 19259763 Applicant CENTRE NATIONAL DE RESEARCHE SCIENTIFIQUE (CNRS) Inventor Martine CERUTTI

The invention relates to a method for producing a recombinant baculovirus comprising n exogenous genes in an insect cell, by means of homologous recombination of a replication-deficient baculovirus genome and n transfer vectors, each comprising one of the n exogenous genes, n being an integer at least equal to 2.

9.WO/2026/090717NOVEL VIRAL PRODUCTION ENHANCERS, METHODS AND USES THEREOF
WO - 07.05.2026
Int.Class C12N 15/87
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
 Appl.No PCT/CA2025/051259 Applicant VIRICA BIOTECH INC. Inventor DIALLO, Jean-Simon
The present application relates to viral sensitizers. More specifically, the present application relates to compounds of Formula (I), as well as methods of using such compounds as viral sensitizers, specifically for increasing permissiveness of a cell to the production of virus from reverse genetics systems, replicating viruses, and increasing transduction. Formula (I).
10.WO/2026/090718NOVEL VIRAL PRODUCTION ENHANCERS, METHODS AND USES THEREOF
WO - 07.05.2026
Int.Class C12N 15/87
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
 Appl.No PCT/CA2025/051265 Applicant VIRICA BIOTECH INC. Inventor DIALLO, Jean-Simon
The present application relates to viral sensitizers. More specifically, the present application relates to compounds, as well as methods of using such compounds as viral sensitizers, specifically for increasing permissiveness of a cell to the production of virus from reverse genetics systems, replicating viruses, and increasing transduction.
# -